These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25753820)

  • 21. Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD?
    Karpen SJ
    Gastroenterology; 2013 Sep; 145(3):508-10. PubMed ID: 23891611
    [No Abstract]   [Full Text] [Related]  

  • 22. The NASH drug dash.
    Chi KR
    Nat Rev Drug Discov; 2015 Jul; 14(7):447-8. PubMed ID: 26129791
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.
    Dajani A; AbuHammour A
    Saudi J Gastroenterol; 2016; 22(2):91-105. PubMed ID: 26997214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obeticholic acid (Ocaliva) for primary biliary cholangitis.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):53-55. PubMed ID: 28323811
    [No Abstract]   [Full Text] [Related]  

  • 26. Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies.
    Jahn D; Rau M; Wohlfahrt J; Hermanns HM; Geier A
    Dig Dis; 2016; 34(4):356-63. PubMed ID: 27170389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease: another leap forward.
    Abdelmalek MF
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):85-86. PubMed ID: 33420415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
    Vignozzi L; Filippi S; Comeglio P; Cellai I; Sarchielli E; Morelli A; Rastrelli G; Maneschi E; Galli A; Vannelli GB; Saad F; Mannucci E; Adorini L; Maggi M
    Mol Cell Endocrinol; 2014 Mar; 384(1-2):143-54. PubMed ID: 24486698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials.
    Zhang C; Yuan W; Fang J; Wang W; He P; Lei J; Wang C
    PLoS One; 2016; 11(8):e0161792. PubMed ID: 27560482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Not Available].
    Pariente A
    Rev Prat; 2015 Feb; 65(2):171. PubMed ID: 25939215
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
    Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
    Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Starting the battle to control non-alcoholic steatohepatitis.
    Ratziu V
    Lancet; 2015 Mar; 385(9972):922-4. PubMed ID: 25468161
    [No Abstract]   [Full Text] [Related]  

  • 35. FXR agonists for NASH: How are they different and what difference do they make?
    Kremoser C
    J Hepatol; 2021 Jul; 75(1):12-15. PubMed ID: 33985820
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacological treatment of NASH].
    Serfaty L
    Presse Med; 2019 Dec; 48(12):1489-1495. PubMed ID: 31757735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies.
    Zeng T; Zhang CL; Zhao XL; Xie KQ
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):646-53. PubMed ID: 24743504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase.
    Choi YJ; Suh HR; Yoon Y; Lee KJ; Kim DG; Kim S; Lee BH
    Arch Pharm Res; 2014; 37(9):1169-76. PubMed ID: 24633463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
    Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
    Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug development: Sprint finish.
    Drew L
    Nature; 2017 Nov; 551(7681):. PubMed ID: 29168826
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.